Suppr超能文献

根治性切除术后肝门部胆管癌的复发率及复发模式

Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection.

作者信息

Groot Koerkamp Bas, Wiggers Jimme K, Allen Peter J, Besselink Marc G, Blumgart Leslie H, Busch Olivier R C, Coelen Robert J, D'Angelica Michael I, DeMatteo Ronald P, Gouma Dirk J, Kingham T Peter, Jarnagin William R, van Gulik Thomas M

机构信息

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Department of Surgery, Academic Medical Center Amsterdam, Amsterdam, The Netherlands.

出版信息

J Am Coll Surg. 2015 Dec;221(6):1041-9. doi: 10.1016/j.jamcollsurg.2015.09.005. Epub 2015 Sep 15.

Abstract

BACKGROUND

The aim of this study was to investigate the rate and pattern of recurrence after curative intent resection of perihilar cholangiocarcinoma (PHC).

STUDY DESIGN

Patients were included from 2 prospectively maintained databases. Recurrences were categorized by site. Time to recurrence and recurrence-free survival (RFS) were estimated using the Kaplan-Meier method. Cox proportional hazards modeling was used to identify independent poor prognostic factors.

RESULTS

Between 1991 and 2012, 306 consecutive patients met inclusion criteria. Median overall survival was 40 months. A recurrence was diagnosed in 177 patients (58%). An initial local recurrence was found in 26% of patients: liver hilum (11%), hepaticojejunostomy (8%), liver resection margin (8%), or distal bile duct remnant (2%). An initial distant recurrence was observed in 40% of patients: retroperitoneal lymph nodes (14%), intrahepatic away from the resection margin (13%), peritoneum (12%), and lungs (8%). Only 18% of patients had an isolated initial local recurrence. The estimated overall recurrence rate was 76% at 8 years. After a recurrence-free period of 5 years, 28% of patients developed a recurrence in the next 3 years. Median RFS was 26 months. Independent prognostic factors for RFS were resection margin, lymph node status, and tumor differentiation. Only node-positive PHC precluded RFS beyond 7 years.

CONCLUSIONS

Perihilar cholangiocarcinoma will recur in most patients (76%) after resection, emphasizing the need for better adjuvant strategies. The high recurrence rate of up to 8 years justifies prolonged surveillance. Only patients with an isolated initial local recurrence (18%) may have benefited from a more extensive resection or liver transplantation. Node-positive PHC appears incurable.

摘要

背景

本研究旨在调查肝门部胆管癌(PHC)根治性切除术后的复发率及复发模式。

研究设计

患者来自2个前瞻性维护的数据库。复发按部位分类。采用Kaplan-Meier法估计复发时间和无复发生存期(RFS)。使用Cox比例风险模型识别独立的不良预后因素。

结果

1991年至2012年期间,306例连续患者符合纳入标准。中位总生存期为40个月。177例患者(58%)被诊断为复发。26%的患者出现初始局部复发:肝门(11%)、肝空肠吻合口(8%)、肝切除边缘(8%)或远端胆管残端(2%)。40%的患者出现初始远处复发:腹膜后淋巴结(14%)、肝内远离切除边缘(13%)、腹膜(12%)和肺(8%)。仅18%的患者有孤立的初始局部复发。8年时估计的总复发率为76%。在5年无复发期后,28%的患者在接下来3年内复发。中位RFS为26个月。RFS的独立预后因素为切除边缘、淋巴结状态和肿瘤分化。仅淋巴结阳性的PHC患者RFS不超过7年。

结论

大多数患者(76%)肝门部胆管癌切除术后会复发,强调需要更好的辅助治疗策略。高达8年的高复发率证明需要延长监测时间。仅孤立初始局部复发的患者(18%)可能从更广泛的切除或肝移植中获益。淋巴结阳性的PHC似乎无法治愈。

相似文献

1
Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection.
J Am Coll Surg. 2015 Dec;221(6):1041-9. doi: 10.1016/j.jamcollsurg.2015.09.005. Epub 2015 Sep 15.
6
Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy.
Clin Transl Oncol. 2015 Oct;17(10):825-9. doi: 10.1007/s12094-015-1312-0. Epub 2015 Jun 4.
7
Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China.
World J Gastroenterol. 2016 Feb 28;22(8):2601-10. doi: 10.3748/wjg.v22.i8.2601.
10
Concomitant hepatic artery resection for advanced perihilar cholangiocarcinoma: a case-control study with propensity score matching.
J Hepatobiliary Pancreat Sci. 2016 Jul;23(7):442-8. doi: 10.1002/jhbp.363. Epub 2016 Jun 9.

引用本文的文献

1
Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma.
Oncol Res. 2025 Aug 28;33(9):2279-2307. doi: 10.32604/or.2025.065319. eCollection 2025.
3
Computational analyses to reveal the key determinants of the high malignancy level of cholangiocarcinoma.
J Transl Int Med. 2025 Jan 10;12(6):602-617. doi: 10.1515/jtim-2024-0033. eCollection 2024 Dec.
4
O‑GlcNAcylation as an emerging molecular target for cholangiocarcinoma therapy (Review).
Oncol Rep. 2025 Oct;54(4). doi: 10.3892/or.2025.8952. Epub 2025 Jul 19.
5
Center Experience Is Associated With Improved Survival in Liver Transplantation for Hilar Cholangiocarcinoma: A Retrospective Study.
Transplant Direct. 2025 Jun 27;11(7):e1822. doi: 10.1097/TXD.0000000000001822. eCollection 2025 Jul.
6
Interobserver variability in lymph node evaluation with endoscopic ultrasonography in cholangiocarcinoma.
Endosc Int Open. 2025 May 12;13:a25775449. doi: 10.1055/a-2577-5449. eCollection 2025.
7
Prognostic role of claudin-18.2 in intrahepatic cholangiocarcinoma.
Virchows Arch. 2025 Mar 28. doi: 10.1007/s00428-025-04081-x.
9
Treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis: a comprehensive review.
eGastroenterology. 2024 Mar 29;2(1):e100045. doi: 10.1136/egastro-2023-100045. eCollection 2024 Jan.

本文引用的文献

1
Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making.
Langenbecks Arch Surg. 2014 Aug;399(6):693-705. doi: 10.1007/s00423-014-1210-x. Epub 2014 May 20.
2
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
Ann Oncol. 2014 Feb;25(2):391-8. doi: 10.1093/annonc/mdt540. Epub 2013 Dec 18.
3
Surgical treatment of 144 cases of hilar cholangiocarcinoma without liver-related mortality.
World J Surg. 2014 May;38(5):1164-76. doi: 10.1007/s00268-013-2394-x.
4
Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma.
J Gastrointest Surg. 2013 Nov;17(11):1917-28. doi: 10.1007/s11605-013-2331-1. Epub 2013 Sep 19.
6
Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome.
J Gastrointest Surg. 2013 May;17(5):913-24. doi: 10.1007/s11605-013-2144-2. Epub 2013 Jan 15.
8
Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma.
Br J Surg. 2013 Jan;100(2):274-83. doi: 10.1002/bjs.8950. Epub 2012 Nov 2.
9
Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre.
ANZ J Surg. 2013 Apr;83(4):268-74. doi: 10.1111/j.1445-2197.2012.06195.x. Epub 2012 Sep 3.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验